Increased plasma Urotensin II (UII) levels have been found in adults with renal diseases. Studies in children are scarce. The objective of the study is to estimate plasma UII levels in subjects with chronic kidney disease (CKD) stages 3 to 5 and renal transplant recipients (RTR). In addition, the correlation of UII with anthropometric features and biochemical parameters was assessed.
Fifty-four subjects, aged 3 to 20 years old, 23 with CKD, 13 with end-stage kidney disease (ESKD) undergoing hemodialysis (HD) and 18 RTR were enrolled. A detailed clinical evaluation was performed. Biochemical parameters of renal and liver function were measured. Plasma UII levels were measured in all patients and in 117 healthy controls, using a high sensitive enzyme immunoassay (EIA) kit. All data were analyzed using STATA™ (Version 10.1).
Median UII and mean log-transformed UII levels were significantly higher in CKD and RTR patients compared to healthy subjects (p < 0.001). HD patients had higher but not statistically significant UII and log-UII levels than controls. UII levels increased significantly at the end of the HD session and were higher than controls and in line to those of other patients. The geometric scores of UII in HD (before dialysis), CKD and RTR patients increased respectively by 42, 136 and 164% in comparison with controls. Metabolic acidosis was associated with statistical significant change in log-UII levels (p = 0.001). Patients with metabolic acidosis had an increase in UII concentration by 76% compared to those without acidosis.
Children and adolescents with CKD, particularly those who are not on HD and RTR, have significantly higher levels of UII than healthy subjects. UII levels increase significantly at the end of the HD session. The presence of metabolic acidosis affects significantly plasma UII levels.
Balat A, Buyukcelik M. Urotensin-II: More than a mediator for kidney. Int J Nephrol 2012; 249790. doi: 10.1155/2012/249790
Ashton N. Renal and vascular actions of urotensin II. Kidney Intern. 2006;70:624–9. CrossRef
Wang T, Li SX, Zhang XQ, Gu XH, Song Y, Zhang G, et al. Study on the effect of adrenomedulin and urotensin-II on pulmonary hypertension of patients with congenital heart disease. Zhonghua Yi Xue Za Zhi. 2005;85(38):2691–5. PubMed
Hogg JR, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: Evaluation, Classification and Stratification. Pediatrics. 2003;111(6):1416–21. CrossRefPubMed
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128 (Suppl 5): S213-256.
Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Urotensin in end- stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol. 2005;18:727–32. PubMed
Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertension. 2001;19:2185–90. CrossRef
Yilmaz B, Yilmaz A, Sari F, Sarikaya AM, Ellidag HY, Kucukseymen S, Ozpelit E. Decrease of Urotensin II activity can impact on the volume status in predialysis chronic kidney disease. Ren Failure. 2015;37(3):476–81. CrossRef
Hursitoglu M, Tukek T, Cikrikcioglu MA, Kara O, Kazancioglu R, Ozkan O, et al. Urotensin II levels in patients with chronic kidney disease and kidney transplants. Upsala J of Med Sciences. 2012;117:22–7. CrossRef
Papadoyannakis NJ, Stefanidis CJ, McGeown M. The effect of the correction of metabolic acidosis on nitrogen and potassium balance of patients with chronic renal failure. Am J Clin Nutr. 1984;40(3):623–7. PubMed
Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR, Bailey JL, Goldberg AL. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest. 1994;93(5):2127–33. CrossRefPubMedPubMedCentral
- Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study
Andromachi J. Mitsioni
Constantinos J. Stefanidis
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II